Girishanthy Krishnarajah of Glaxo-SmithKline presented a cost-effectiveness analysis of a one-time Boostrix
vaccination among a cohort of U.S.
M2 EQUITYBITES-July 11, 2011-GlaxoSmithKline plc awarded FDA approval for BOOSTRIX
for whooping cough treatment in adults 65 years and older(C)2011 M2 COMMUNICATIONS http://www.m2.com
Food and Drug Administration (FDA) recently approved Boostrix
vaccine manufactured by GlaxoSmithKline Biologicals to prevent tetanus, diphtheria, and pertussis (whooping cough) in people ages 65 and older.
vaccine (Tdap).(Minimum age: 10 years for Boostrix
and 11 years
is a combined vaccine of tetanus, diphtheria and acellular pertussis, or Tdap, and is licensed for use in 10-18 year olds.
New vaccines include Cervarix for human papillomavirus, Rotarix for rotavirus, Fluarix for influenza and Boostrix
28) and the committee's June 2005 recommendation to use Tdap among 11- to 12-year-olds at the routine adolescent visit (using either Adacel, which is licensed for use in persons aged 11-64 years, or GlaxoSmithKline's Tdap, Boostrix
, which is licensed only for ages 10-18).
Of the two currently licensed Tdap vaccines, only GlaxoSmithKline's Boostrix
is approved for adults aged 65 and older.
vaccine has been approved for use in people aged 65 years and older to prevent tetanus, diphtheria, and pertussis, the FDA announced.